Document Xz0JmB9dBDVzYgXv7Qz1176pg

KSaathvriinePEr.eRseeendt, PhD. ISMaiElavOipceornamteinontsal Hes and . BeHR030%-00373 970000PBBaou,xsh3M3ANv3e1nSuse,13B33u33l1n 42:26:20 ST Mest 27353 2267694 coon F E49-33907 AKR2267/6T IM im 2 Document Processing Center ESRER | , EPA East -- Room 6428 Attn: Section 8() Officeof Pollution Prevention and Toxics SH z OR 2% US EPA Co, =3 1200 Pennsylvania Avenue NW Washington DC 20460-0001 Np",Uhr =3 a, RE: TSCA 8(E) SUPPLEMENTAL SUBMISSION: Io o Docket No. 8EHQ-1180-373 Ay Dear Sirs: 3M has received final results for an oral pharmacokinetic study in rats conducted with perfluorooctanesulfonyl fluoride (POSF, CAS 307-35-7) indicating that the test substance metabolizes to perfluorooctane sulfonate (PFOS, CASH 2795-39-3). `The study was conducted by 3M's Strategic Toxicology Laboratory. A single oral dose ofS mg/kg POSF was administered to 15 male rats. Necropsies were performed otonPdFaOysS.1, M4,aaxnidm2u9mpPosFtOdSosien.thTehelivsetruodcycruersrueldtsoinnddicaa4tye tphoasttPdOosSeFawt aasppmreotxaibmoaltiezleyd 11 ppm, or 10%ofthe dose. On days 1 and 29 post dose, the PFOS concentration in the liver was 7 and 4 ppm, respectively. POSF was used as an intermediate gas in an isolated industrial process to produce PFOS and related products. 3M no longer manufactures POS. Enclosed please find the final study titled "Pharmacokinetic Study of Perfluorooctancsulfonyl Fluoride (POS) Following a Single Oral Gavage Dose in Rats" Please contact Andrew Seacat (651-575-3161)ifyou have any questions orifwe can provide additional information. Sincerely, Dosh. Cabs ved SAatheune 3 StaffVice President Environmental, Health and Safety Operations Enclosure = dri 5 52 gepa-ore pp 5FE 3o%o piss 5Tan o2